dpp-4 inhibitors and glp-1 agonists Clinical Use of GLP-1-RA and DPP-4 inhibitors in
Description
Decisions made today across manufacturing and commercialisation will determine which companies are best positioned as these therapies move from promise to scale

Stopping Treatment Appetite may increase, leading to weight regain

Lancet Diabetes Endocrinol

Dunn, T

Not only can this epidemic lead to disrupting comorbidities, but statistics show [3] that it also significantly increases mortality rates worldwide [4]
